MK-1439

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Absorption, distribution, metabolism and elimination of doravirine (MK-1439), a novel non-nucleoside reverse transcriptase… (More)
Is this relevant?
2017
2017
INTRODUCTION Doravirine, a non-nucleoside reverse-transcriptase inhibitor in development for the treatment of patients with human… (More)
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2017
2017
RATIONALE During the development of a novel synthetic route to doravirine (1), a human immunodeficiency type 1 virus (HIV-1… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Doravirine (DOR, formerly known as MK-1439) is a human immunodeficiency type 1 virus (HIV-1) nonnucleoside reverse transcriptase… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2014
2014
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a mainstay of therapy for treating human immunodeficiency type 1… (More)
Is this relevant?
2014
2014
INTRODUCTION Doravirine (DOR) is an investigational NNRTI (aka MK-1439) that retains activity against common NNRTI-resistant… (More)
Is this relevant?
2014
2014
The optimization of a novel series of non-nucleoside reverse transcriptase inhibitors (NNRTI) led to the identification of… (More)
Is this relevant?
2014
2014
There are 28 approved antiretroviral drugs for the treatment of HIV infection; combinations of these drugs clearly change the… (More)
Is this relevant?
Review
2013
Review
2013
PURPOSE OF REVIEW A number of investigational antiretroviral drugs in clinical development could alter the future treatment… (More)
Is this relevant?
Review
2012
Review
2012
Numerous investigational antiretroviral agents are in clinical development. Among them are festinavir (BMS986001), a thymidine… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?